Anatomical and Clinical Study of Liver Steatosis Severity as a Predictor of Sudden Unexpected Death in Metabolic Syndrome
DOI:
https://doi.org/10.53350/pjmhs2023177198Keywords:
Liver steatosis, metabolic syndrome, sudden unexpected death, myocardial fibrosis, preventive medicine, forensic autopsy, cardiac remodeling.Abstract
Background: Metabolic syndrome is a disorder that impacts on several organ systems and liver steatosis has risen as a possible marker of more profound metabolic damage. Knowledge on whether the severity of steatosis is a predictor of sudden unexpected death could help to elucidate the relationship between the liver and the heart in a case of advanced metabolic disease. The paper has analyzed the clinical and anatomical value of steatosis severity in postmortem cases, whose findings can be used in preventive medicine and in autopsies.
Methodology: The analytical clinico-anatomy research was carried out between January 2022 and January 2023 in Khairpur Medical College, Khairpur Mir's. Eighty two consecutive cases of medico-legal autopsies that met diagnostic criteria of metabolic syndrome were included. Demographic data, microscopic liver and cardiac, and comprehensive histopathological were noted. They were statistically compared, correlated and odds ratios to determine the relationship between the severity of steatosis and sudden unexpected death.
Results: Severe steatosis was much more prevalent with sudden death cases and was characterized by increased grades of inflammation, advanced stages of fibrosis, and increased chances of steatohepatitis. The same pattern was observed in cardiac abnormalities which included increased heart weight, left ventricular hypertrophy and myocardial fibrosis where there was a close association with the severity of hepatic injury. Severe steatosis was a predictive factor of sudden unexpected death (p < 0.001), and there was also evidence that showed that liver pathology and cardiac remodelling were connected through a common metabolic pathway.
Conclusion: The severity of liver steatosis is a valuable anatomical predictor of people with metabolic syndrome that could be prone to sudden unexpected death. These results underscore the importance of steatosis assessment in clinical prevention and forensic studies in which early detection of severe hepatic involvement can be used to emphasize individuals with high risk.
References
Elsaid, M.I., et al., Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. 2022. 1(3): p. 445-456.
Lin, A., et al., Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study. 2021. 20(1): p. 27.
Lonardo, A., et al., History of nonalcoholic fatty liver disease. 2020. 21(16): p. 5888.
Yao, Y., et al., Obesity and sudden cardiac death: Prevalence, pathogenesis, prevention and intervention. 2022. 10: p. 1044923.
Koo, B.K., S.J.C.O.i.A. Lim, and Children, 13 Metabolic Syndrome and Metabolic. 2022: p. 5186172.
Tuzzolo, A., et al., Severe myocardial steatosis: incidental finding or a significant anatomic substrate for sudden cardiac arrest? 2020. 41(1): p. 42-47.
Kheirvari, M., et al., The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. 2020. 6(2).
Menendez, A., et al., Obesity and adipose tissue dysfunction: from pediatrics to adults. 2022. 13(10): p. 1866.
Northup, P.G., et al., Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. 2021. 73(1): p. 366-413.
Lefere, S., et al., Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆. 2020. 73(4): p. 757-770.
Jia, F., et al., Sex difference in circulating PCSK9 and its clinical implications. 2022. 13: p. 953845.
King, B. and A. Blom. Complement in metabolic disease: metaflammation and a two-edged sword. in Seminars in Immunopathology. 2021. Springer.
Sarkar, M., et al., Reproductive health and liver disease: practice guidance by the American Association for the Study of Liver Diseases. 2021. 73(1): p. 318-365.
Trujillo, M.J., et al., Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review. 2021. 78: p. 22-34.
Tahani, N., et al., Consensus clinical management guidelines for Alström syndrome. 2020. 15(1): p. 253.
Deguise, M.-O., L. Chehade, and R.J.I.J.o.M.S. Kothary, Metabolic dysfunction in spinal muscular atrophy. 2021. 22(11): p. 5913.
Lim, K., et al., Lipodistrophy: a paradigm for understanding the consequences of “overloading” adipose tissue. 2021. 101(3): p. 907-993.
Katoch, S. and V.J.J.o.a.t. Patial, Zebrafish: An emerging model system to study liver diseases and related drug discovery. 2021. 41(1): p. 33-51.
Cheng, X.S., et al., Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association. 2022. 146(21): p. e299-e324.
Toro-Pérez, J. and R.J.R.R. Rodrigo, Contribution of oxidative stress in the mechanisms of postoperative complications and multiple organ dysfunction syndrome. 2021. 26(1): p. 35-44.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2023 Abdullah Khilji, Rajesh, Hina Rukhsar, Muhammad Rafique Shaikh
This work is licensed under a Creative Commons Attribution 4.0 International License.
